<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03265509</url>
  </required_header>
  <id_info>
    <org_study_id>2014/1203</org_study_id>
    <nct_id>NCT03265509</nct_id>
  </id_info>
  <brief_title>Effect of Glutamine on Urinary Incontinence</brief_title>
  <official_title>Assessment of the Effect of Glutamine Supplementation in Addition to Exercise on Pelvic Floor Muscle Strength and Clinical Parameters in Women With Urinary Incontinence or Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestl√©</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine to effect of additional oral glutamine to Kegel
      exercises on pelvic floor strength and clinical parameters of urinary incontinence in females
      with either urinary incontinence (stress and/or urgency) and pelvic prolapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary incontinence is a prevalent and costly condition that affects approximately 38% of
      older community-dwelling women (age&gt;60 years). Incontinence predisposes patients to other
      health problems, contributes to depression and social isolation, is a significant source of
      dependency among the elderly, and is widely cited as a factor in nursing home admissions.
      Sarcopenia is age-related and is characterized by loss of muscle mass, strength and
      endurance. There is not only a decrease in the number of muscle fibers, but also atrophy in
      the remaining ones. Several studies indicate glutamine supplementations lead to better muscle
      performance by stimulate muscle producing in extremities. Similarly, we assume glutamine
      supplementation could increase pelvic muscle mass and improve the pelvic floor strength. From
      this point, using glutamine supplementation may effect positively on stress, urge or mixed
      incontinence, and pelvic prolapse.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pelvic floor muscle strength</measure>
    <time_frame>3 months</time_frame>
    <description>vaginal dynamometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pelvic floor muscle strength</measure>
    <time_frame>3 months</time_frame>
    <description>digital vaginal palpation method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>3 months</time_frame>
    <description>muscle mass assessed by bioimpedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Prolapse quality of life (PQOL) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>King's Health Questionnaire (KHQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour pad test</measure>
    <time_frame>3 months</time_frame>
    <description>assessment of the severity of urinary incontinence as determined by the 24-hour pad weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hand grip strength</measure>
    <time_frame>3 months</time_frame>
    <description>Jamar hand dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary incontinence dairy</measure>
    <time_frame>3 months</time_frame>
    <description>urinary incontinence dairy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>degree of prolapse</measure>
    <time_frame>3 months</time_frame>
    <description>systematic pelvic examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Glutamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 g/day Glutamine supplementation for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fantomalt</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 g/day Fantomalt supplementation for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>glutamine supplementation</intervention_name>
    <description>30 g/day glutamine supplementation for three months</description>
    <arm_group_label>Glutamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fantomalt supplementation</intervention_name>
    <description>30 g/day fantomalt supplementation for three months</description>
    <arm_group_label>Fantomalt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of urinary incontinence and/or pelvic prolapse and/or decreased vaginal
             muscle strength in gynaecological examination

        Exclusion Criteria:

          -  Uncontrolled diabetes

          -  Cognitive dysfunction hampering participation in exercise or assessment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gulistan Bahat Ozturk, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University Istanbul Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gulistan Bahat Ozturk, Ass. Prof.</last_name>
    <phone>00902124142000</phone>
    <phone_ext>31478</phone_ext>
    <email>gbahatozturk@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istanbul University Istanbul Faculty of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birkan Ilhan, Fellow</last_name>
      <phone>00902124142000</phone>
      <phone_ext>31478</phone_ext>
      <email>birkanilhan@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2017</study_first_submitted>
  <study_first_submitted_qc>August 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Gulistan Bahat-Ozturk</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

